# Some setbacks...supply chain issues & higher expenses mainly affecting products division. Also delays in Technology Division sales, but this division will have miniscule role in revenue generation going forward & it will focus on servicing the business internally with no proactive efforts at external sales.
# Gross margins remained stable but EBITDA margins contracted for both Products ( 18% from 23% in PCP) & Services (26% from 31%).....This is not good & hopefully temporary.
# A shift to expansion.
Good acquisition in WA ...Cash & equity.....No debt component.
More focus on USA expasion.
Technology division downsized for internal purposes rathe than lisencing.
# Still maintaing $60m revenue target in 2025.....But it is more important to restore EBITDA margins to historical levels of 30%+.
- Forums
- ASX - By Stock
- Ann: LaserBond Dec 23 Half-Year Performance Summary
LBL
laserbond limited
Add to My Watchlist
0.00%
!
36.0¢

# Some setbacks...supply chain issues & higher expenses mainly...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
36.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $42.35M |
Open | High | Low | Value | Volume |
36.0¢ | 36.5¢ | 36.0¢ | $31.12K | 85.78K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 82542 | 36.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.5¢ | 22457 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 82542 | 0.360 |
3 | 39547 | 0.355 |
3 | 12328 | 0.350 |
2 | 31428 | 0.345 |
4 | 18141 | 0.340 |
Price($) | Vol. | No. |
---|---|---|
0.365 | 22457 | 1 |
0.370 | 11577 | 2 |
0.380 | 75000 | 2 |
0.385 | 60000 | 2 |
0.390 | 43000 | 1 |
Last trade - 13.41pm 25/06/2025 (20 minute delay) ? |
Featured News
LBL (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
SPONSORED BY The Market Online